Autoinjectors Market

Market Insights

With a growing trend towards the self-administration of drugs, injectable drug delivery solutions such as autoinjectors and pen injectors demonstrate noteworthy growth potential in the near future. Driven by industry demands, biopharmaceutical companies worldwide have since introduced a wide range of drug injection solutions. In fact, it is also estimated that a significant portion of new product entries to the FDA will be drug-device combinations. Among these, autoinjectors are the fastest-emerging drug delivery solution that augments patient experience and overcomes compliance concerns by allowing drug administration at home.

Apart from patient advantages, reducing the number of clinic visits assists in reducing treatment costs for healthcare providers and reducing the burden on healthcare personnel. Safety mechanisms and ergonomic designs have helped in addressing dexterity issues faced by patients and avoiding the risk of needle-stick injuries.

For the purpose of this report, the global autoinjectors market is studied by device types, therapeutic areas, and geography. Based on device types, this market is segmented into manual injection autoinjectors, automated injection autoinjectors, reusable autoinjectors, disposable autoinjectors, variable dose autoinjectors, and smart autoinjectors. Anaphylaxis, anticoagulants, autoimmune diseases, emergency medicine, infectious diseases, hematopoietic systems, hormones, neurology, and reproductive health are the chief therapeutic areas where autoinjectors are used. Market size and forecasts for the period 2013–2022, along with respective CAGRs for the forecast duration of 2016–2022, are provided in this report for each considered segment.

Based on geographic distribution, the global autoinjectors market is studied for the following regional and country-level markets:

• North America
  • US.
  • Canada
• Europe
  • Germany
  • France
  • UK.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Market size and forecast, along with respective CAGRs for the considered periods, are provided in this section cumulatively for the overall segments.

Along with quantitative information sets, this report includes market assessments in terms of major commercial events mapping and analysis of the major drivers, restraints, and opportunities prevalent in the autoinjector market. In addition, competition analysis tools such as attractive investment propositions and competitive analysis by key market players are also provided in this study for scrutinizing the prevalent competition in the global autoinjectors market. This report concludes with profiles of key companies engaged in the development, manufacturing, and sale of autoinjectors in international markets.

The global autoinjectors market is studied for the following device types:

• Manual Injection Autoinjectors
• Automated Injection Autoinjectors

Reusable autoinjectors

• Disposable Autoinjectors
• variable-dose autoinjectors
• Smart Autoinjectors

The autoinjector market is technology-driven and dynamic, with swift movements and developments taking place. These devices are gradually overtaking the dominance of conventional self-injection devices. Pediatrics is anticipated to witness the fastest adoption of autoinjectors. Manual injectors are the largest segment in the considered device categories. Offered benefits over conventional self-injection systems, such as overcoming the risk of needle-stick injury and improving treatment compliance. The reduced need to visit clinics has led to an overall reduction in treatment costs and improved treatment outcomes. The introduction of biologics for drug delivery, better patient adherence, simplified self-administration, and the growing incidence of chronic diseases are the key drivers facilitating the growth of this market.

Based on therapeutic areas, the global autoinjectors market is studied for the following types:

• Anaphylaxis
• Hormones
• Anticoagulants
• Emergency Medicine
• Autoimmune Diseases
• Infectious Diseases
• Hematopoietic
• Neurology
• Reproductive Health

Anaphylaxis is the largest therapeutic area where autoinjectors are widely used. Adrenaline autoinjectors are prescribed to patients with allergies who are at a higher risk of having severe reactions, i.e., anaphylaxis. The available autoinjectors across all therapeutic areas are prescription-only and must be prescribed by general practitioners or allergy specialists. Doses for all the considered therapeutic areas are dependent on the stage of the condition, age, and other such parameters. The use of adrenaline and epinephrine injectors is anticipated to further augment pediatrics, particularly in high-income countries where the incidence of allergies among children is phenomenally high.Geographically, the autoinjectors market is cumulative across North America, Europe, Asia-Pacific, the Middle East, Africa, and Latin America.

The detailed regional classification of this market is as follows:

• North America (U.S. and Canada)
• Europe (U.K., Germany, and the Rest of Europe)
• Asia-Pacific (Japan, China, and the Rest of Asia-Pacific)
• Middle East and Africa
• Latin America

North America is the largest market for autoinjectors. High disease prevalence, swift technological developments, first-in-line approval for novel products, high healthcare expenditure, favorable reimbursements, and quick adoption of new therapeutic solutions are the key factors driving the dominance of the North American autoinjectors market. Asia Pacific is anticipated to progress at the fastest growth rate during the forecast period.

Factors such as growing awareness among patients and caregivers, growing healthcare expenditure, and the rapid development of healthcare infrastructure are the key drivers of the Asia Pacific autoinjectors market. Government initiatives, public and private partnerships, and an augmenting market for reproductive health are some of the other factors supporting the growth of this region.

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Autoinjectors Market, by Devices, 2015 (USD Mn)
2.2 Autoinjectors Market Share, by Therapeutic Area, 2015 (Value %)
2.3 Autoinjectors Market Share, by Geography, 2015 (Value %)

Chapter 3 Autoinjectors Market: Market Dynamics and Outlook
3.1 Introduction, Facts and Figures
3.2 Drivers
3.3 Challenges
3.4 Opportunities
3.5 Major Market Events Assessment
3.6 Attractive Investment Proposition
3.7 Competitive Analysis: Autoinjectors Market, by Key Market Players

Chapter 4 Global Autoinjectors Market Analysis, by Devices, 2013 – 2022 (USD Mn)
4.1 Preface
4.2 Manual Injection Autoinjectors
4.3 Automated Injection Autoinjectors
4.4 Reusable Autoinjectors
4.5 Disposable Autoinjectors
4.6 Variable Dose Autoinjectors
4.7 Smart Autoinjectors

Chapter 5 Global Autoinjectors Market Analysis, by Therapeutic Area, 2013 – 2022 (USD Mn)
5.1 Preface
5.2 Anaphylaxis
5.3 Anticoagulants
5.4 Autoimmune Diseases
5.5 Emergency Medicine
5.6 Infectious Diseases
5.7 Hematopoietics
5.8 Hormones
5.9 Neurology
5.10 Reproductive Health

Chapter 6 Global Autoinjectors Market Analysis, by Geography, 2013 – 2022 (USD Mn)
6.1 Preface
6.2 North America
6.2.1 United States
6.2.2 Canada
6.3 Europe
6.3.1 United Kingdom
6.3.2 Germany
6.3.3 Rest of Europe
6.4 Asia Pacific
6.4.1 Japan
6.4.2 China
6.4.3 Rest of Asia Pacific
6.5 Middle East and Africa (MEA)
6.6 Latin America

Chapter 7 Company Profiles
7.1 Biogen Idec, Inc.
7.1.1 Business Description
7.1.2 Financial Health and Budget Allocation
7.1.3 Product Positions/Portfolio
7.1.4 News Coverage
7.2 Becton, Dickinson and Company
7.2.1 Business Description
7.2.2 Financial Health and Budget Allocation
7.2.3 Product Positions/Portfolio
7.2.4 News Coverage
7.3 Antares Pharma, Inc.
7.3.1 Business Description
7.3.2 Financial Health and Budget Allocation
7.3.3 Product Positions/Portfolio
7.3.4 News Coverage
7.4 Mylan, Inc.
7.4.1 Business Description
7.4.2 Financial Health and Budget Allocation
7.4.3 Product Positions/Portfolio
7.4.4 News Coverage
7.5 Novartis International AG
7.5.1 Business Description
7.5.2 Financial Health and Budget Allocation
7.5.3 Product Positions/Portfolio
7.5.4 News Coverage
7.6 Unilife Corporation
7.6.1 Business Description
7.6.2 Financial Health and Budget Allocation
7.6.3 Product Positions/Portfolio
7.6.4 News Coverage
7.7 Pfizer, Inc.
7.7.1 Business Description
7.7.2 Financial Health and Budget Allocation
7.7.3 Product Positions/Portfolio
7.7.4 News Coverage
7.8 Scandinavian Health Ltd.
7.8.1 Business Description
7.8.2 Financial Health and Budget Allocation
7.8.3 Product Positions/Portfolio
7.8.4 News Coverage
7.9 Ypsomed Holding AG,
7.9.1 Business Description
7.9.2 Financial Health and Budget Allocation
7.9.3 Product Positions/Portfolio
7.9.4 News Coverage
7.10 Sanofi S. A.
7.10.1 Business Description
7.10.2 Financial Health and Budget Allocation
7.10.3 Product Positions/Portfolio
7.10.4 News Coverage
7.11 Bayer AG
7.11.1 Business Description
7.11.2 Financial Health and Budget Allocation
7.11.3 Product Positions/Portfolio
7.11.4 News Coverage
7.12 Emergent BioSolutions
7.12.1 Business Description
7.12.2 Financial Health and Budget Allocation
7.12.3 Product Positions/Portfolio
7.12.4 News Coverage
7.13 Other Notable Payers

List of Figures

FIG. 1 Autoinjectors: Market Segmentation
FIG. 2 Autoinjectors Market, by Devices, 2015 (USD Mn)
FIG. 3 Autoinjectors Market, by Therapeutic Area, 2015 (Value %)
FIG. 4 Autoinjectors Market Share, by Geography, 2015 (Value %)
FIG. 5 Attractive Investment Proposition, Autoinjectors Market, 2015
FIG. 6 Competitive Analysis: Autoinjectors Market, by Key Market Players
FIG. 7 Global Manual Injection Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 8 Global Automated Injection Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 9 Global Reusable Autoinjectors Market, 2014-2022 (USD Mn)
FIG. 10 Global Disposable Autoinjectors Market, 2014-2022 (USD Mn)
FIG. 11 Global Variable Dose Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 12 Global Smart Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 13 Global Anaphylaxis Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 14 Global Anticoagulants Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 15 Global Autoimmune Diseases Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 16 Global Emergency Medicine Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 17 Global Infectious Diseases Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 18 Global Hematopoietic Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 19 Global Hormone Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 20 Global Neurology Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 21 Global Reproductive Health Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 22 United States Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 23 Canada Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 24 United Kingdom Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 25 Germany Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 26 Rest of Europe Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 27 Japan Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 28 China Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 29 Rest of Asia Pacific Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 30 Middle East and Africa Autoinjectors Market, 2013 – 2022 (USD Mn)
FIG. 31 Latin America Autoinjectors Market, 2013 – 2022 (USD Mn)

List of Tables

TABLE 1 Global Autoinjectors Market, by Devices, 2013 – 2022 (USD Mn)
TABLE 2 Global Autoinjectors Market, by Therapeutic Area, 2013 – 2022 (USD Mn)
TABLE 3 Global Autoinjectors Market, by Geography, 2013 – 2022 (USD Mn)
TABLE 4 North America Autoinjectors Market, by Country, 2013 – 2022 (USD Mn)
TABLE 5 Europe Autoinjectors Market, by Country, 2013 – 2022 (USD Mn)
TABLE 6 Asia Pacific Autoinjectors Market, by Country, 2013 – 2022 (USD Mn)